Benefits
Higher blood levels of free curcuminoids
In a randomized trial in 60 adults, blood levels of free (unconjugated) curcuminoids were about 31 times higher after a single 500 mg dose and about 39 times higher after 30 days of 500 mg twice daily than with standard unformulated curcumin. The trial was run with researchers from the manufacturer.
Stress, anxiety and fatigue scores
Adults with work-related stress took 500 mg twice daily of CurQfen, standard curcumin or placebo for 30 days. The CurQfen group reported lower stress, anxiety and fatigue and better quality of life than the standard curcumin group, with higher blood antioxidant markers. It was a 60-person pilot trial with manufacturer-affiliated authors.
Cognitive and movement scores in older adults
In a six-month trial in 48 older adults with moderate dementia, 400 mg twice daily of CurQfen improved scores on a standard cognitive test (MMSE) and a locomotive function scale compared with placebo and with standard curcumin, alongside changes in blood BDNF and other markers. Three authors were employed by the manufacturer.
Knee joint comfort and walking performance
In a six-week open-label trial (84 randomized, 72 completed) in adults with knee osteoarthritis, 400 mg once daily improved pain ratings, WOMAC scores and walking performance from baseline, and the authors reported larger gains than with glucosamine plus chondroitin. The trial was not blinded and several authors worked for the manufacturer.
Healthy liver enzyme levels
In an 8-week double-blind trial, 48 adults with long-term heavy alcohol use and raised liver enzymes took 250 mg twice daily or placebo. Transaminases fell about 31% and GGT about 29% from baseline with CurQfen, while values rose about 9.5% with placebo. This is one small trial with manufacturer-affiliated authors and has not been repeated.
Inflammatory marker support (IL-6, TNF-alpha, CRP)
Blood IL-6 and TNF-alpha fell in the six-month cognition trial, IL-6 and CRP fell in the liver enzyme trial, and serum inflammatory markers fell in the knee trial. Each was a small trial with manufacturer-linked authors, and these are lab markers rather than outcomes people feel.
HDL cholesterol and homocysteine in obese young men
In a 12-week double-blind trial in 22 obese men aged 18 to 35, 500 mg/day raised HDL cholesterol and lowered homocysteine compared with fenugreek fiber alone. Endothelial function, central blood pressure, glucose, insulin and oxidative stress markers did not change. One author worked for the manufacturer.
Mechanism of action
Fenugreek fiber complex
Curcuminoids are combined with fenugreek galactomannan, a soluble fiber, to form a complex its developers call curcumagalactomannoside (CGM). Human pharmacokinetic data show higher blood levels of free curcuminoids than standard curcumin.
Free curcuminoids versus conjugates
Most absorbed curcumin is quickly converted to glucuronide and sulfate conjugates. Free curcuminoids are considered more biologically active and better able to cross membranes, which is the rationale for a formulation that raises free levels.
Brain delivery in animal studies
Rat studies reported better blood-brain barrier permeability and tissue distribution for this formulation than for standard curcumin. Brain levels have not been shown in people.
NF-kB and inflammatory signaling
In laboratory studies, curcuminoids act on NF-kB and other inflammatory signaling pathways, the same mechanism proposed for other curcumin forms.
Antioxidant and NRF2 activity
Curcumin has direct antioxidant activity and can switch on the body's own antioxidant defenses through NRF2 in laboratory studies. In the stress trial, CurQfen raised blood antioxidant markers and lowered lipid peroxidation.
Clinical trials
Randomized, double-blind, placebo-controlled three-arm pilot trial: CurQfen vs standard curcumin vs placebo, 500 mg twice daily for 30 days (Pandaran Sudheeran et al. 2016, J Clin Psychopharmacol).
60 adults with work-related stress, anxiety and fatigue.
Compared with the standard curcumin group, the CurQfen group had better quality of life (P<0.05) and lower stress, anxiety and fatigue scores (all P<0.001), with higher antioxidant markers and lower lipid peroxidation. Free curcuminoid absorption was 30.7-fold (single dose) and 39.1-fold (repeated dose) higher than standard curcumin. Authors included manufacturer staff.
Randomized, double-blind, placebo-controlled three-arm trial: CurQfen vs standard 95% curcumin vs placebo, 400 mg twice daily for six months (Das et al. 2023, Front Dement).
48 adults with moderate dementia at the onset of Alzheimer's disease (16 per group).
CurQfen improved MMSE and Geriatric Locomotive Function Scale scores and serum BDNF, amyloid beta 42, tau, IL-6 and TNF-alpha compared with placebo and standard curcumin (P<0.05). Small trial; three authors were employed by the manufacturer.
Randomized, open-label, active-controlled trial: CurQfen 400 mg once daily vs glucosamine 500 mg plus chondroitin 415 mg twice daily for 6 weeks (Thomas et al. 2021, Phytother Res).
84 adults with knee osteoarthritis randomized; 72 completed.
From baseline, CurQfen improved VAS pain by 47%, KPS by 21%, walking performance by 206% and total WOMAC by 35%, with lower serum inflammatory markers; the authors reported larger gains than with glucosamine plus chondroitin. Open-label design and manufacturer-employed authors limit confidence.
Randomized, double-blind, placebo-controlled trial: CurQfen 250 mg twice daily (dose corrected by the authors in a 2019 corrigendum) or placebo for 8 weeks (Krishnareddy et al. 2018, Biomed Res Int).
48 adults with chronic alcohol use and raised transaminases and GGT (24 per group).
Transaminases fell 31% and GGT 29% from baseline with CurQfen, while placebo values rose about 9.5%. Glutathione, SOD and GPx rose and IL-6 and CRP fell versus baseline and placebo (P<0.001). One small trial; most authors worked for the manufacturer.
Randomized, double-blind, controlled trial: CurQfen 500 mg/day vs fenugreek fiber alone for 12 weeks (Campbell et al. 2019, Nutrition).
22 obese men aged 18 to 35 (BMI 30 or higher).
Homocysteine fell and HDL cholesterol rose versus control (both P=0.04). Glucose, insulin, leptin, adiponectin, oxidative stress markers, endothelial function, augmentation index and central blood pressure did not change versus control. One author worked for the manufacturer.
Prospective 90-day safety study of CurQfen 1,000 mg/day (about 380 mg curcuminoids) (Pancholi et al. 2021, Toxicol Rep).
20 healthy adult volunteers.
No adverse effects and no clinically significant changes in vital signs, blood counts, lipids, kidney markers or liver enzymes (AST, ALT, ALP, GGT, bilirubin). Uncontrolled and small; authors included manufacturer staff.